Klinische Pädiatrie

Editorial

Fulda, S:

Editorial

•      
• Abstract

A1

Houghton, PJ; Cam, H:

Dysregulation of mTORC1 Signaling in Childhood Solid Tumors

•      
• Abstract

A2

Sorensen, P:

Tyrosine Kinase Networks in Pediatric Cancer

•      
• Abstract

A3

Helman, LJ:

Targeting the IGF1 Pathway in Pediatric Sarcomas

•      
• Abstract

A4

Corbacioglu, S:

The RIST Strategy: Molecular-Based Multimodal Treatment Regimens in Pediatric Oncology

•      
• Abstract

A5

Suttorp, M; Tauer, JT; Jaeger, BAS; Rosen-Wolff, A:

Balancing Benefits and Risk During Treatment of Paediatric Patients (pts) with Chronic Myeloid Leukaemia (CML) by Tyrosine Kinase Inhibitors (TKI)

•      
• Abstract

A6

Burdach, S:

Targeting Epigenetic Maintenance of Stemness in Pediatric Malignancy

•      
• Abstract

A7

Witt, O; Deubzer, H; Oehme, I; Milde, T:

Targeting HDACs in Pediatric Oncology

•      
• Abstract

A8

De Jong, S; De Vries, EGE:

Targeting TRAIL Death Receptors: TRAIL from the Lab to the Clinic

•      
• Abstract

A9

Letai, A:

BH3 Profiling – A Predictive Biomarker for Apoptotic Response to Chemotherapy

•      
• Abstract

A10

Fulda, S:

Targeting Apoptosis Pathways for the Treatment of Pediatric Cancers

•      
• Abstract

A11

Schäfer, BW:

Therapeutic Strategies Targeting Oncogenic Fusion Proteins in Sarcomas

•      
• Abstract

A12

Hahn, H; Nitzki, F; Zibat, A; Uhmann, A; Ecke, I; Rosenberger, A; Witt, O; Schulz-Schaeffer, W:

Hedgehog Signaling: A Therapeutic Target in Embryonal Rhabdomyosarcoma?

•      
• Abstract

A13

Eggert, A; Schulte, JH; Astrahantseff, K; Pajtler, K; Künkele, A; Schramm, A:

Molecular Targets in Embryonal Tumors

•      
• Abstract

A14

Berthold, F; Fischer, M:

Novel Targeted Agents in Neuroblastoma

•      
• Abstract

A15

Schulte, JH:

Lysine-Specific Demethylase 1 is Strongly Expressed in Poorly Differentiated Neuroblastoma: Implications for Therapy

•      
• Abstract

A16

Kovar, H; Kauer, M; Mesdagh, P; Ban, J; Niedan, S; Jug, G; Speleman, F; Poremba, C; Aryee, D:

The "Ideal" Target's Network: Factors Modulating EWS-FLI1 Expression and Function in Ewing's Sarcoma

•      
• Abstract

A17

Potratz, J; Sorensen, P:

RNA Interference Screening to Identify Novel Therapeutic Targets

•      
• Abstract

A18

Molenaar, JJ; Westerhout, EM; Den Boer, ML; Clifford, SC; Delattre, O; Geoerger, B; Lanvers, C; Pietsch, T; Serra, M; Shipley, J; Vassal, G; Versteeg, R; Verschuur, AC; Caron, HN:

The KidsCancerKinome: Validation of Cell Cycle Genes as Potential Drug Targets in Pediatric Tumors

•      
• Abstract

A19

Kappler, R:

The Hedgehog Signaling Pathway as a Therapeutic Target in Pediatric Liver Tumors

•      
• Abstract

A20

Pfister, S:

Potential of Molecular Targeted Therapies in Childhood Brain Tumors (BRAF Inhibitors)

•      
• Abstract

A21

Rutkowski, S; Bueren, AO von:

Molecular-Targeted Therapies for Childhood Medulloblastoma

•      
• Abstract

A22

Wolff, JE; Brown, R; Thall, P; Pfister, S:

Personalized Targeted Therapy for Refractory Pediatric Brain Tumors Program: Concept and Preliminary Clinical Experience

•      
• Abstract

A23

Houghton, PJ:

Development of Novel Therapy for Childhood Cancer: Promise and Challenges

•      
• Abstract

A24

Caron, HN; Westerhout, EM; Kool, M; Molenaar, JJ; Stroeken, PJ; Den Boer, M; Segers, S; Clifford, S; Delattre, O; Geoerger, B; Benetkiewicz, M; Lanvers, C; Warps, R; Pieters, R; Pietsch, T; Holst, M; Renshaw, J; Serra, M; Scotlandi, K; Shipley, J; Vassal, G; Degrand, O; Verschuur, AC; Versteeg, R:

The KidsCancerKinome – Validation of Drug Targets for High Risk Childhood Cancers

•      
• Abstract

A25

Geoerger, B; Vassal, G:

Innovative Therapies for Children with Cancer (ITCC): Clinical Trial Program

•      
• Abstract

A26

Herold, R; Raymond, AS:

Regulatory and Scientific Support for Developing Innovative Medicines for Children with Cancer

•      
• Abstract

A27

Ritter, J:

The Etiology of Acute Childhood Leukemias

•      
• Abstract

A28

Stanulla, M; Cario, G; Meissner, B; Breithaupt, P; Schrauder, A; Möricke, A; Bourquin, JP; Schrappe, M:

Early Diagnosis and Targeted Treatment of Very High-Risk Childhood Acute Lymphoblastic Leukemia – The I-BFM Approach

•      
• Abstract

A29

Bourquin, JP:

Xenotransplantation in Immunodeficient Mice to Evaluate New Therapeutic Strategies for Refractory Childhood Acute Lymphoblastic Leukemia

•      
• Abstract

A30

Schrappe, M; Möricke, A; Schrauder, A; Cario, G; Mann, G; Valsecchi, MG; Zimmermann, M; Stanulla, M; Conter, V:

Clinical Goals of Targeted Therapy in Childhood ALL

•      
• Abstract

A31

Jeremias, I; Ehrhardt, H; Höfig, I; Terziyska, N; Obexer, P:

NOXA as Target for the Combination Therapy of Betulinic Acid and Conventional Cytotoxic Drugs

•      
• Abstract

A32

Fakler, M; Löder, S; Vogler, M; Schneider, K; Jeremias, I; Debatin, KM; Fulda, S:

Targeting IAP Proteins to Sensitize Childhood Acute Leukemia Cells for Apoptosis

•      
• Abstract

A33

Rettinger, E; Kuçi, S; Kuçi, Z; Weber, G; Willasch, A; Kreyenberg, H; Koehl, U; Von Laer, D; Fulda, S; Klingebiel, T; Bader, P:

Enhancing Cytotoxicity of Cytokine-Induced Killer (CIK) Cells against Refractory Leukemia

•      
• Abstract

A34

Debatin, KM:

Cell Death Pathways: Sensitivity and Resistance in Leukemia

•      
• Abstract

A35

Kulozik, AE; Kox, C; Remke, M; Breit, S; Zimmermann, M; Stanulla, M; Schrappe, M; Muckenthaler, MU:

The Role of Activated NOTCH Signaling in Childhood T-ALL

•      
• Abstract

A36

Borkhardt, A:

The Expanding Family of ALK-Mediated Malignancies in Childhood

•      
• Abstract

A37

Binder, V:

Hsa-mir-125b-2 is Highly Expressed in Childhood ETV6/RUNX1 (TEL/AML1) Leukemias and Confers Survival Advantage to Growth Inhibitory Signals Independent of P53

•      
• Abstract

A38

Gombert, M:

High-Throughput Mutation Analysis of Tyrosine Kinome in Childhood AML

•      
• Abstract

A39

Queudeville, M; Eckhoff, SM; Debatin, KM; Meyer, LH:

Single-cell Phospho-Profiling in Pediatric B-cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Reveals Signaling Differences in Cytogenetic and Prognostic Subgroups

•      
• Abstract